This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • HAL-MPE1 First-in-human (HAL-MPE1/0043)
Clinical trial

HAL-MPE1 First-in-human (HAL-MPE1/0043)

Read time: 1 mins
Last updated:5th Jun 2014

Currently, there is no effective causal treatment for peanut allergy. A chemically modified, aluminium hydroxide adsorbed peanut extract (HAL-MPE1) for subcutaneous administration has been developed. Results from in vitro and in vivo preclinical studies demonstrate the immunotherapeutic potential of HAL-MPE1. Therefore, a phase I, single-centre clinical trial has been designed to assess the safety and tolerability of HAL-MPE1 in peanut allergic patients.

Category Value
Study start date 2014-06-05

View full details